AIDA — Aida Pharmaceuticals Share Price
Last Trade - 00:00- $0.19m
- $39.55m
- $37.51m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008E | 2009E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 15.64 | 24.53 | 29.64 | 29.2 | n/a | n/a | 534.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -20.62 | +6.69 | +74.29 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AIDA Pharmaceuticals, Inc., located in Hangzhou, the People’s Republic of China, operates through its subsidiaries, which include Earjoy Group Limited (Earjoy), Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida), Hangzhou Boda Medical Research and Development Co., Ltd. (Boda), Hainan Aike Pharmaceutical Co., Ltd. (Aike), Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) and Shanghai Qiaer Bio-technology Co., Ltd (Qiaer). Earjoy is an investment holding company. Hangzhou Aida is a pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in mainland China. Hangzhou Aida has a total of nine production lines for the manufacture of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. Hangzhou Aida’s primary product is the injectable powder form of Etimicin Sulfate.
Directors
- Last Annual
- December 31st, 2007
- Last Interim
- September 30th, 2008
- Incorporated
- December 18th, 2002
- Public Since
- July 5th, 2006
- No. of Shareholders
- 50
- No. of Employees
- 450
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 27,000,000
- Address
- 31 Dingjiang Road, Jianggan District, HANGZHOU, 310016
- Web
- http://babyken.a32.53dns.com/
- Phone
- +86 57185802712
- Auditors
- Weinaug & Co.
Similar to AIDA
ACUSPHERE ORD
Pink Sheets on Nasdaq
ANBC ORD
Pink Sheets on Nasdaq
AOXING PHARMACEUTICAL ORD
Pink Sheets on Nasdaq
EMERGENT HEALTH ORD
Pink Sheets on Nasdaq
INTEGRATED PHARMACEUTICALS ORD
Pink Sheets on Nasdaq
FAQ
As of Today at 19:57 UTC, shares in Aida Pharmaceuticals are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Aida Pharmaceuticals last closed at $0.01 and the price had moved by -88.33% over the past 365 days. In terms of relative price strength the Aida Pharmaceuticals share price has underperformed the S&P500 Index by -90.97% over the past year.
There is no consensus recommendation for this security.
Aida Pharmaceuticals does not currently pay a dividend.
Aida Pharmaceuticals does not currently pay a dividend.
Aida Pharmaceuticals does not currently pay a dividend.
To buy shares in Aida Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Aida Pharmaceuticals had a market capitalisation of $0.19m.
Here are the trading details for Aida Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AIDA
Based on an overall assessment of its quality, value and momentum Aida Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aida Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -87.02%.
As of the last closing price of $0.01, shares in Aida Pharmaceuticals were trading -76.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aida Pharmaceuticals.
Aida Pharmaceuticals' management team is headed by:
- Biao Jin -
- Hui Lin -
- Yuejun Jiang -
- Jiajun Qiu -
- Qiong Zhang -
We do not have data on Aida Pharmaceuticals' shareholders